An analysis of the profile of the expression of genes important for an effective response to cetuximab (anti-EGFR-targeted agent) therapy in 80 CRC tumors allowed for the identification of six clinically relevant CRC subtypes. This evidence concerns the gene EGFR and colorectal carcinoma.